Healthy Brains for Healthy Lives (HBHL) Fellowship
15 Aug 2019

Congrats to Alexa, Hazal and Pierre on receiving Healthy Brains for Healthy Lives (HBHL) Fellowship for the upcoming year. 

A warm welcome to Frédéric and Jordana, our new lab members!
15 Aug 2019

We would like to give a warm welcome to two new lab members: Frédéric St-Onge and Jordana Remz. Frédéric joined us from Quebec City as our new doctoral student. Frédéric will aim to predict, as early as possible, cognitively healthy individuals who will develop cognitive impairment over time, using a combination of clinical and neuroimaging variables. Jordana is currently working on different modalities in neuroimaging and focuses her efforts on the automation of data processing. You can read more about Frédéric and Jordana, including their previous work and some of their interests, on our people page.  

The Alzheimer’s Association International Conference (AAIC2019)
July 14th-18th, 2019

The Alzheimer’s Association International Conference (AAIC) 2019 conference took place in Los Angeles from July 14 –18. Dr. Villeneuve, along with Julie Gonneaud, Alexa Pichet Binette, Theresa Köbe, and Pierre-François Meyer attended to the AAIC to present some of their recent work. Alexa, Julie, and Theresa presented their posters at the conference and Pierre-Francois gave a talk about his work. [Photos


Douglas Research Day
11 June 2019

2019 Annual Research Day of Douglas Hospital Research Centre and McGill Department of Psychiatry was on Tuesday, June 11, 2019. This is an important event, which highlights the vital contributions of our students and postdocs to the Douglas and McGill communities. Pierre-Francois Meyer gave a presentation, while Theresa Kobe and Melissa McSweeney presented their posters. [Photos]


9 June 2019

The Organization for Human Brain Mapping (OHBM) 2019 conference took place in Rome from June 9 – 13. OHBM brings together researchers from all over the world who have made cutting-edge neuroscientific discoveries with the use of neuroimaging. At OHBM, Alexa Pichet Binette presented her poster “Gray matter volume and whole-brain pattern organization across the lifespan and Alzheimer’s disease”.


First Annual Canadian Open Neuroscience (CONP) Meeting
29 April 2019

The Canadian Open Neuroscience Platform (CONP) is a large open data pool where researchers can publish, share, and access neuroscience research data. It improves the accessibility of data with the goal of collaboration among researchers, research efficiency, and rapid scientific discovery. The first annual meeting of CONP took place at the end of April in Toronto. Dr. Sylvia Villeneuve and Jennifer Tremblay-Mercier took part in the two-day conference which featured talks about open neuroscience’s role in accelerating scientific breakthroughs and how researchers can maintain the accessibility of freely available data.


16 April 2019

In April 2019, the Canadian television series Discovery visited 3 laboratories at the Douglas for their segment covering Artificial Intelligence and new discoveries in the field of Alzheimer’s research. Dr. Judes Poirier and Dr. Villeneuve’s lab took part in this filming session as well as Dr Mallar Chakravarti, a PREVENT-AD collaborator. We would like to extend a special thanks to the participants who generously agreed to be in the eye of the camera, and were filmed during their PET scan, MRI scan, and while playing with the crew to enact “fake” memory testing. The episode will air on SRC in September. We will keep you posted on the air date and time!



QBIN Scientific Day

29 March 2019

Villeneuve lab members Theresa, Pierre, and Alexa presented their recent projects using poster and video presentations at the 11th Quebec Bio-Imaging Network (QBIN) scientific day.

Image result for hbhl





New CIHR grant for the Villeneuve lab
23 January 2019

We are happy to announce that Dr. Villeneuve have received a 5-year grant from the Canadian Institutes of Health Research for the project entitled “Preventing the progression of Alzheimer’s disease pathology by targeting the effects of lifestyle factors and personality traits.

Principal Investigator: Villeneuve, Sylvia C
Co-Investigators: Breitner, John C; Collins, D. Louis; Poirier, Judes; Rajah, M. Natasha N; Soucy, Jean-Paul; Vachon-Presseau, Etienne

Read Abstract

There are over half a million Canadians living with dementia, the leading cause being Alzheimer’s disease (AD). Amyloid and tau are the pathological hallmarks of AD. They start to accumulate between one and two decades before memory impairment. We know that the apolipoprotein (APOE) 4 allele, the main genetic risk factor for AD, influences amyloid and tau accumulation. It is unclear if other factors, such as lifestyle factors (e.g. education and cognitive activity) or personality traits (e.g. optimism and neuroticism), can also modify amyloid and tau accumulation and/or if these factors can buffer the deleterious effect of APOE4 on AD pathology accumulation. Lifestyle and personality traits are of interest because they are modifiable (particularly lifestyle) and, therefore, could be prime targets for prevention efforts. The first objective of this proposal is to determine the lifestyle factors and personality traits that are associated with amyloid and tau burden in cognitively normal older adults at risk of developing AD dementia. The second objective is to determine if some lifestyle/personality factors can counteract the negative effects of APOE4 on AD pathology accumulation. Finally, we want to test if the lifestyle/personality factors can delay the clinical onset of the disease by buffering the negative impact of AD pathology on cognition. Finally, we will test if the factors influencing AD pathology differ between men and women, since we know that women are at increased risk of developing AD dementia. This work will be done in collaboration with the PREVENT-AD, a cohort of almost 400 cognitively normal or very mildly impaired older adults who have a parental history of AD-like dementia. It will focus on 120 individuals that did a brain scan to quantify amyloid and tau in vivo. This multidisciplinary study will give insights about new, sex-specific prevention strategies.

Human Amyloid Imaging conference 2019
16-18 January 2019

Dr. Villeneuve, along with Theresa, Alexa, Pierre, and Melissa attended this year’s Human Amyloid Imaging (HAI) conference in Miami to present some of their recent work. You can check their posters here: [Posters]

[photo gallery]

Villeneuve lab welcomes Anne Maass
7 January 2019

Anne is a post-doctoral researcher at DNZE Magdeburg Site, Germany. She will collaborate with the Villeneuve lab to study the relations between memory dysregulation and amyloid and tau proteins using task-fMRI data from Prevent-AD.

MAIN 2018 and McConnell BIC Retreat
10 December 2018

Congratulationss to Julie Gonneaud for receiving best poster and best abstract prizes from the Montreal AI & Neuroscience (MAIN) conference 2018 and McConnell BIC retreat event for her recent project entitled “The preclinical phase of autosomal dominant Alzheimer’s disease is characterized by accelerated brain aging.” [poster]

Lab’s Christmas dinner
6 December 2018

A very warm Merry Christmas to all, from the Villeneuve lab team.

NeuroQAM 2018
22 November 2018

Alexa presented her research entitled “Behavioral factors are differentially associated with amyloid and tau burden in older adults with a family history of Alzheimer’s disease” at the NeuroQAM Science day 2018 for which she received the best oral presentation award.

PREVENT-AD Gala 2018
15 November 2018

 On November 15, the annual gala event was held for the participants of the PREVENT-AD study. The day was punctuated by presentations by Drs. Judes Poirier and Sylvia Villeneuve on the latest advances in Alzheimer’s disease research and future developments in the study. During the meal, participants, researchers, and students were able to talk together. A huge thank you to our participants who, as always, showed much dedication and involvement this year.  [Photo gallery]


Douglas Research Blitz
14 November 2018

Villeneuve lab members Mari-Elise, Theresa, Morteza, and Kaitlin presented the progress of their research projects to other students and faculty at the Douglas Hospital Research Blitz event.


Lab Retreat 2018
22-25 October 2018

The annual Villeneuve lab’s retreat took place at La Conception, Quebec. For three days, the team explored novel research ideas through brainstorming sessions and hackathons, while enjoying the picturesque nature and home-cooked foods together. [Photo gallery]



[Photo gallery]

Dr. William Klunk lecture at MNI
15 October 2018

Dr. Villeneuve alongside Julie, Alexa, and Morteza attended Dr. William E. Klunks lecture on “Amyloid Imaging: Influence of Very Advanced Age and Genetic Alterations” at Montreal Neurological Institute.
Dr Klunk is one of the most renowned researcher in the field of amyloid PET imaging. In 2001, Dr. Klunk and colleagues created the PiB tracer, allowing for the first time a non-invasive method for quantifying Alzheimer’s pathology in humans.




Sixth Biennial Conference on Brain Connectivity
24-29 September 2018

Villeneuve Lab members: Julie, Theresa, Alexa, Morteza, and Melissa attended the educational course organized alongside the 6th Biennial Conference on Rest State and Connectivity that was held in Montreal this year. They learned more about cutting-edge structural and functional connectivity analyses, as well as the utility of machine learning algorithms in neuroimaging.
Julie and Alexa also attended the main conference. Julie presented her most recent project, a predictive model of age based on functional connectivity to then look at differences in the preclinical phase of AD [poster].

Group photo recreated in the style of brain connectivity artwork using the DeepArt machine learning algorithm.

Sander Verfaillie defends his thesis
12 September 2018

Dr Villeneuve has been invited to the VU University of Amsterdam in Netherlands as an external member of the Sander Verfaillie thesis defence committee. Sander was a Ph.D. candidate at the Alzheimer Center of the VU University Medical Center and worked on subjective memory complaints by integrating PET and MRI imaging. He joined Villeneuve lab in 2016-17 for a research project. The results of his project were recently published [Paper].
Sander defended his thesis entitled “Neuroimaging in subjective cognitive decline: incipient Alzheimer’s disease unmasked” with great success. Congratulations!




AAIC 2018 presentations & posters
19-25 July 2018

Dr. Villeneuve, along with Julie Gonneaud, Alexa Pichet Binette, Theresa Kobe, Melissa McSweeney, Pierre-François Meyer and Etienne Vachon-Presseau attended this year’s AAIC conference in Chicago to present some of their recent work. Alexa, Melissa, and Pierre gave a talk about their work, and Theresa and Julie presented their posters at the conference. [Photos]


CSHRF 2018
12-15 Jun 2018

Alexa presented her work on associations of neuropsychiatric and personality factors with amyloid and tau PET measures. An insight into how these characteristics may shape AD risk. Pierre presented work showing that CSF protein markers of key AD-related biological pathways may indicate resilience to Alzheimer pathology. Alexa and Pierre received a CIHR Honorable Mention and Gold award respectively for their presentations at CSHRF 2018! Congratulations to you both!

22 Jun 2018

Last week, on Friday, June 22th, the Villeneuve lab students attended the 3rd edition of the NeuroSymposium. This symposium is an inter-university initiative whose aim is to build an active community of young neuroscientists across Quebec. This great initiative is organized by students across the province, and Alexa is among to co-founders of the event. Melissa presented her work and other lab members helped during the day.

Douglas Research Day
5 Jun 2018

2018 Annual Research Day of Douglas Hospital Research Centre and McGill Department of Psychiatry was on last Tuesday, June 5, 2018. This is an important event, which highlights the vital contributions of our students and postdocs to the Douglas and McGill communities. Julie and Pierre gave a presentation, while Alexa and Melissa presented their posters. Prizes were awarded for the best oral and poster presentations and Alexa won the prize for “Best Poster Presentation”. [Photos]


“Biomarkers for neurodegenerative diseases” course at the University of Gothenburg
26 Apr 2018

Pierre and Alexa attended the graduate course “Biomarkers for neurodegenerative diseases” at the University of Gothenburg in Sweden, organized by Drs. Michael Schöll, Henrik Zetterberg, Kerstin Heurling & Kaj Blennow. The week was filled with talks related to CSF and PET biomarkers by leading experts in the field. It was a fun and productive week in the beautiful city of Gothenburg!


A warm welcome to Morteza, our new rotation program Ph.D. student!
23 Apr 2018

We would like to give a warm welcome to our new lab member Morteza Pishnamazi. Morteza joined us from Tehran, Iran as a Rotation program Ph.D. student in the Integrated Program in Neuroscience at McGill University. At Villeneuve Lab, he will study the association between baseline Aβ and tau deposition loads and temporal changes in gray matter volume in pre-symptomatic senile individuals at risk of developing Alzheimer’s disease.
You can read more about Morteza, including their previous work and some of their interests, on our people page.


Congratulations to Melissa, Alexa, Julie, Pierre, and Theresa!
29 Mar 2018

Their abstracts got accepted and they will be presenting their work at Villeneuve Lab at both Alzheimer’s Imaging Consortium (AIC) and Alzheimer’s Association International Conference (AAIC) which will take place in Chicago on July 2018.
Melissa: “Early Increase in Tau-PET Signal Is Associated with Aβ Burden, CSF p-Tau Levels, and Cognition in Cognitively Normal Late-Middle-Aged Adults
Alexa: “Neuropsychiatric Burden Is Related to Increased Amyloid but Not Tau Deposition in Late-Middle-Aged Cognitively Normal Individuals with a Family History of Alzheimer’s Disease”
Julie: “Genetic and Environmental Factors Are Differentially Related to Aβ Burden in the Presymptomatic Phase of Autosomal Dominant and Sporadic Alzheimer’s Disease”
Theresa: “Cerebral GABA, resting-state functional connectivity and memory function in Alzheimer’s disease”
Pierre: “CSF Immune Markers Predict Decreased AD Symptom Severity and Progression”


A warm welcome to Theresa, our new postdoctoral student!
15 Mar 2018

We would like to give a warm welcome to our new lab member Theresa Köbe. Theresa joined us from Berlin, Germany as a Postdoctoral Student. Her project here focuses on the impact of vascular burden on preclinical Alzheimer’s disease pathology.
You can read more about Theresa, including their previous work and some of their interests, on our people page.

Villeneuve Lab in Media
12 Mar 2018

The Alzforum weekly newsletter featured an article by Madolyn Bowman Rogers covering Dr. Villeneuve’s paper. You can read the article here.26 Feb 2018Dr. Villeneuve and her team had the chance to be interviewed by TVA and Radio Canada on February 26th. The interviews are about Dr. Villeneuve’s recent publication on the link between amyloid accumulation and proximity to parental symptom onset in individuals with a family history of Alzheimer’s disease. You can watch the interview with TVA here and the one with Radio-Canada here. You can also access the press release published by McGill University on this study here.


New Article by Sylvia Villeneuve
26 Feb 2018

A new article by Dr. Villeneuve: “Proximity to parental symptom onset and amyloid burden in sporadic Alzheimer’s disease”, has been published in JAMA Neurology. This study shows that as individuals with a family history of sporadic AD approach the age of their parent at symptom onset, they are more likely to show amyloid burden. This finding was confirmed in three different cohorts and was independent of their biological age.

Human Amyloid Imaging Conference 2018
17-19 Jan 2018

Dr. Villeneuve, along with Julie Gonneaud and Alexa Pichet Binette attended this year’s HAI conference in Miami to present some of their recent works. Julie gave a talk comparing sporadic AD and autosomal dominant AD, and Alexa presented her poster at the conference. [Photos]


New Article by Villeneuve Lab alumnus Sander Verfaillie
14 Dec 2017

A new article by Sander Verfaillie, “Subjective cognitive decline is associated with altered default mode network connectivity in individuals with a family history of Alzheimer’s Disease” published in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging feature research on the subjective cognitive decline, brain connectivity pattern and family history of dementia.



Happy New Years! Our Lab Christmas Party 2017
7 Dec 2017

The Villeneuve Lab wishes everyone a happy new year! Photos

Human Amyloid Imaging Conference
2 Dec 2017

Congrats to Julie on receiving Human Amyloid Imaging conference travel fellowship to attend at the conference that will be held in January 17-19, 2018 in Miami, FL.


Réseau De Bio-Imagerie Du Québec Scholarship
2 Dec 2017

Congrats to Julie and Melissa on receiving Réseau De Bio-Imagerie Du Québec scholarship (RBIC-QBIN) for the upcoming conference. Julie was ranked first amongst 57 participants.

Julie Gonneaud

Melissa McSweeney
New Article in Journal of Neuroscience
30 Oct 2017

A new article “White matter structure in older adults moderates the benefit of sleep spindles on motor memory consolidation” published in Journal of Neuroscience features research on memory, brain structure, and sleep.


New Article in Journal of Labelled Compounds and Radiopharmaceuticals
5 Oct 2017

A new article “Highly efficient solid phase-supported radiosynthesis of [11 C]PiB using tC18 cartridge as a “3-in-1” production entity.” published in Journal of Labelled Compounds and Radiopharmaceuticals features research on Amyloid imaging and Positron Emission Tomography.


A warm welcome to Melissa, our new lab member
25 Sep 2017

We would like to give a warm welcome to our new lab member Melissa McSweeney. Melissa joined us from Chicago as a master’s Student. Her project here focuses on the roles of sleep and cognitive fluctuations in Alzheimer’s disease. Melissa already presented her previous work during Integrated Program in Neuroscience Retreat with Alexa. We are excited to work with her and know she will contribute significantly to our lab’s growth.
You can read more about Melissa, including their previous work and some of their interests, on our people page.

Lab Retreat 2017
17-20 Aug 2017

The Villeneuve Lab enjoyed a retreat at Sainte-Anne-des-Lacs. The team worked on the upcoming projects. We also enjoyed the beautiful nature and some delicious food afterward!

AAIC 2017 posters
20 Jul 2017

The posters, which were presented by Dr. Villeneuve, along with students Alexa Pichet Binette and Pierre-François Meyer, and consultant Etienne Vachon-Presseau at this year’s AAIC conference in London, are now available on our website  [link to posters].


Villeneuve Lab attends AAIC 2017
20 Jul 2017

Dr. Villeneuve, along with students Alexa Pichet Binette and Pierre-François Meyer, and consultant Etienne Vachon-Presseau attended this year’s AAIC conference in London to present some of their recent work [link to posters]. Villeneuve Lab alumnus Sander Verfaille was also in attendance, and gave a talk on subjective cognitive complaints; a project he worked on during his time in the lab.

Alzheimer’s Association Travel Awards
17 Apr 2017

Congrats to Pierre et Alexa who received travel awards from the Alzheimer’s Association to attend/assist at the international Alzheimer’s Conference (AAIC) that will be held in July in London.


Welcome to new lab members Julie and Sander
26 Sep 2016

We would like to give a warm welcome to two new lab members: Julie Gonneaud and Sander Verfaillie. Julie comes to us from France as a postdoctoral researcher. Her project here focuses on the detection of early biomarker changes in asymptomatic individuals with a familial risk of Alzheimer’s Disease. Sander hails from the Netherlands and is here as a graduate researcher. His Ph.D. project aims to investigate the earliest brain changes leading to Alzheimer’s Disease in cognitively intact individuals.
You can read more about Julie and Sander, including their previous work and some of their interests, on our people page.

Julie Gonneaud

Sander Verfaillie


Villeneuve Lab at the AAIC Alzheimer’s Imaging Consortium
02 Sep 2016

A recent article on Alzforum noted the presence of the Villeneuve Lab at the AAIC, particularly Jake Vogel’s presentation. The article is entitled “Amyloid and Neurodegeneration Have Different Underlying Genetics.”
Jake Vogel gave his AAIC talk on AD-like patterns of gray matter volume, default mode network connectivity and their association with time till parental symptom onset in sporadic Alzheimer’s disease.
Alexa Pichet Binette also presented a poster at AAIC 2016, relating high CSF tau to reduced hippocampal volume and subjective cognitive decline in healthy elderly with amyloid pathology.You can find more Villeneuve Lab posters and presentations under the Publications heading above.


Jake Vogel presenting at AAIC

Jake Vogel presenting at AAIC

Alexa Pichet Binette presenting her poster at AAIC

Alexa Pichet Binette presenting her poster at AAIC


Dr. Villeneuve received two project grants from the CIHR
17 Jul 2016

Dr. Villeneuve received one of the grants as a principal investigator, and the other as a co-investigator – both from the Canadian Institutes of Health Research.
The first project aims to establish a better understanding of the impact of vascular health on Alzheimer’s disease pathology and clinical expression.

Principal Investigator: Villeneuve, Sylvia C
Co-Investigators: Breitner, John C; Evans, Alan C; Gauthier, Serge G; Hoge, Richard D; Poirier, Judes; Rosa-Neto, Pedro

Read Abstract

Alzheimer’s disease is the most common form of dementia, affecting nearly 50% of Canadians over 80 years of age. With the aging of the population, the prevalence of dementia is expected to increase dramatically, generating major social and economic costs. Currently, Alzheimer’s disease has no known cure, and by the time a person meets the clinical diagnosis for Alzheimer’s disease, brain and cognitive changes related to the disease are already probably irreversible. It is therefore essential to find ways to delay, slow down, or even prevent this devastating disease. Amyloid and tau are the pathological hallmarks of the disease. Vascular risk factors (i.e. hypertension, dyslipidemia, and diabetes) are well-known risk factors for Alzheimer’ disease in addition of being risk factors for vascular brain injuries, which also increase the likelihood of dementia. The advent of amyloid positron emission tomography (PET) imaging now allows for assessing the interplay between vascular risk factors and Alzheimer’s pathology in-vivo. Amyloid PET imaging has helped establish that vascular risk factors can increase the risk of Alzheimer’s disease via pathways that directly related to amyloid pathology. The current research proposal will explore mechanisms by which vascular factors may increase the risk of Alzheimer’s disease. More specifically we propose a series of experiments to explore mechanisms by which genetic (e.g. ApoE and other genes related to both Alzheimer’s disease and vascular health) and lifestyle risk factors (e.g. hypertension and diet) may impact brain change and memory deficits. This study will be conducted in cognitively normal and mildly impaired individuals with a family history of Alzheimer’s disease. The overall goal is to identify new preventive strategies that may delay the onset of Alzheimer’s disease.

The second project aims to investigate the distinctive neuropathology underlying abnormal cognitive decline in remotely concussed former athletes.
Principal Investigator: De Beaumont, Louis
Evans, Alan C; Gauthier, Serge G; Henry, Luke C; Poirier, Judes; Tremblay, Sébastien; Villeneuve, Sylvia C

Read Abstract

The annual prevalence of sports concussion has reached epidemic proportions, making any long-term consequence of the injury sizable in both human and economic terms. Important questions regarding susceptibility and resistance to the long term effects of sports concussion and precisely what they are and how they evolve atop the dynamic substrate of the brain abound. Any discussion of these downstream consequences inevitably leads to chronic traumatic encephalopathy (CTE), the neurodegenerative disease that is widely believed to be the signature pathology of injuries involving recurrent blows to the head occurring during the practice of contact sports. However, from a scientific standpoint, there are several important gaps in what is known about CTE, making causal links premature, to say the least. Typically, when a new disease/pathology is discovered, the natural progression is to move toward prospective research designs where covariates are accounted for. The current research program proposes a longitudinal investigation aiming to assess the predictive value of in vivo markers of neurodegeneration in the rate of progression and specificity of cognitive/behavioral decline in remotely concussed former athletes. This proposal aims to establish the distinctive neuropathology underlying abnormal cognitive functioning in remotely concussed former athletes. Knowing about the signature pathology of the long term effects of concussion will ultimately help us design optimal treatment and prevention strategies aiming to maintain/restore the quality of life of millions of former athletes with a history of remote concussions.


Dr. Villeneuve in the office
Three New Grants for the Villeneuve Lab
25 Jun 2016

Congratulations to Alexa Pichet Binette and Jake Vogel, both of whom received grants this month. Alexa received an Alzheimer’s Society of Canada doctoral scholarship of $60,000 to study the early vascular brain changes and related protective factors in elderly at risk of Alzheimer’s disease. Jacob received an Alzheimer’s Imaging Consortium travel scholarship and an Alzheimer’s Association International Conference travel scholarship.
Dr. Villeneuve also received the Biomedical New Investigator Grant this month, jointly funded by the Alzheimer’s Society of Canada and Brain Canada. The grant consists of  $225,000, for tracking Alzheimer’s disease progression at the earliest stages using amyloid and tau PET scans.



The PERFORM committee’s first methodological workshop
20 May 2016

The PERFORM Applied Bioimaging Centre, run out of Concordia University, is a unique facility that aims to improve health through prevention.  The centre hosted their first Methodological Workshop on May 20th, 2016, on the topic of “Longitudinal Analysis with Neuroimaging Data”. Dr. Villeneuve was an invited speaker, giving a talk on Imaging Amyloid Proteins in Aging and Dementia. The inaugural event was a great success!

 PERFORM Committee(from left to right)
Louis Bherer, Pedro Antonio Valdés-Sosa, Sylvia Villeneuve, Alan C. Evans, Felix Carbonell, Mallar Chakravarty, Habib Benali, Pierre Bellec, Christophe Grova 
Dr. Villeneuve received an Alzheimer’s Association Research Grant
24 Apr 2016

The grant was for $100,000 to develop an online platform to assess health and lifestyle habits in a cohort of ~300 cognitively normal individuals with a family history of Alzheimer’s disease.


Dr. Villeneuve received funding from the John R. Evans Leaders Fund
Feb 2016

The John R. Evans Leaders Fund (JELF) is described as a “strategic investment tool designed to help institutions attract and retain the very best of today’s and tomorrow’s researchers funding”. The funding is associated with a Canada Research Chair amounting to $250,000.


Dr. Villeneuve received a Canada Research Chair
Jan 2016

The chair is in Early Prevention of Alzheimer’s Disease and consists of $500,000.